In 2023, China Chamber of Commerce of Medical & Health Products Importers & Exporters (CCCMHPIE) successively announced three batches of export brand certificates for companies recommended by CCCMHPIE in FY2023. 

A number of in vitro diagnostic (IVD) companies have passed the evaluation and won the "Certificate of China Export Commodity Brand" issued by China Council for the Promotion of International Trade.

The first batch includes IVD companies: C.D.RICH, Clongene Biotech, Acon Biotech, TAILORED MEDICAL, Microprofit, Sansure, Konsung, HIGHTOP and Kanghua Biotechnology.

The second batch includes Autobio, HymonBio, Kehua, TianLong, GenSure Biotech, IMPROVE MEDICAL, Biotest Biotech and WANTAI.

The third batch includes Coretests, Deep Blue, ALLTEST, BIOBASE and Boson. 

About the Certificate

The Certificate of China Export Commodity Brand is a special business added by China Council for the Promotion of International Trade in coordination with the national brand strategy. It can be described as "national endorsement" to examine and certify the export commodity brands of enterprises from eight dimensions, including R&D innovation ability, international certification, market recognition, intellectual property protection and global operation. Its legitimacy and effectiveness are accepted by governments, customs, chambers of commerce, and enterprises in over 200 countries and regions around the world, and it has a wide overseas recognition.